ArticleBMC women's health2026
Absence of high-risk human papillomavirus in breast cancer tissues from young BRCA1/BRCA2-negative women.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HPV DNA Detection and Genotyping in Basal-Like Breast Carcinoma: Insights into a Possible Viral Association.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman papillomavirus (HPV) has been investigated as a potential risk factor in breast cancer, but the literature remains inconsistent. Although biological mechanisms involving HPV E6/E7 oncogene activity provide biological plausibility for viral involvement, reproducible evidence in breast tumors is lacking. This study aimed to determine whether high-risk HPV is detectable or transcriptionally active in breast cancer tissues from young women negative for BRCA1/BRCA2 mutations.
methodsThis retrospective, single-center study included women younger than 50 years with confirmed BRCA1/BRCA2-negative breast cancer. Formalin-fixed, paraffin-embedded tumor specimens were analyzed for high-risk HPV DNA using a PCR-based assay targeting HPV-16, HPV-18, and pooled high-risk genotypes. A subset of tumors with sufficient residual FFPE material and laboratory acceptance for FFPE-based RNA testing also underwent high-risk HPV E6/E7 mRNA analysis to assess transcriptional activity.
resultsNinety women contributed 91 breast cancer specimens. Demographic, reproductive, and pathological features were consistent with typical early-onset breast cancer. High-risk HPV DNA was not detected in any tumor specimen. All mRNA analyses were also negative, indicating absence of transcriptionally active viral oncogene expression.
conclusionsHigh-risk HPV was neither detectable nor transcriptionally active in breast cancer tissues from young BRCA1/BRCA2-negative women. These findings do not support a role for high-risk HPV in breast carcinogenesis in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.